Msefsl

CLOSE X

Risk Disclosures on Derivatives

>9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
>On an average, loss makers registered net trading loss close to ₹ 50,000.
>Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
>Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.

BHARAT PARENTERALS LTD.

NSE : NABSE : 541096ISIN CODE : INE365Y01019Industry : Pharmaceuticals & DrugsHouse : Private

BSE1128.8067.8 (+6.39 %)

PREV CLOSE ( ) 1061.00

OPEN PRICE ( ) 1098.65

BID PRICE (QTY) 0.00 (0)

OFFER PRICE (QTY) 0.00 (0)

VOLUME 630

TODAY'S LOW / HIGH ( )1097.95 1129.95

52 WK LOW / HIGH ( ) 8021771.95

NSE

This Company is not listed in NSE

Select year

Particulars

Mar 2025

Mar 2024

Mar 2023

Mar 2022

Mar 2021

Operational & Financial Ratios

Earnings Per Share (Rs)

-18.32

24.94

28.40

36.46

35.59

CEPS(Rs)

-12.12

33.57

37.40

47.57

45.98

DPS(Rs)

1.00

0.75

0.00

Book NAV/Share(Rs)

479.79

338.96

315.63

287.16

250.34

Tax Rate(%)

-28.64

43.84

33.26

25.34

25.10

Margin Ratios

Core EBITDA Margin(%)

0.79

10.32

9.17

11.58

10.67

EBIT Margin(%)

-6.15

8.68

11.99

12.11

11.79

Pre Tax Margin(%)

-9.95

7.14

10.80

11.57

11.47

PAT Margin (%)

-12.80

4.01

7.21

8.64

8.59

Cash Profit Margin (%)

-2.45

7.45

9.91

11.40

11.14

Performance Ratios

ROA(%)

-7.52

2.46

5.45

9.80

10.52

ROE(%)

-16.55

5.54

9.03

13.46

15.53

ROCE(%)

-4.85

7.74

12.57

17.18

20.24

Asset Turnover(x)

0.59

0.61

0.76

1.13

1.23

Sales/Fixed Asset(x)

1.18

1.56

2.85

3.35

3.80

Working Capital/Sales(x)

2.51

3.63

3.38

2.36

2.27

Efficiency Ratios

Fixed Capital/Sales(x)

0.85

0.64

0.35

0.30

0.26

Receivable days

167.45

176.78

155.57

106.98

113.54

Inventory Days

71.34

69.16

49.06

32.72

39.53

Payable days

131.49

127.69

99.70

66.97

93.48

Valuation Parameters

PER(x)

0.00

44.99

11.83

9.36

9.42

PCE(x)

-81.47

33.43

8.98

7.18

7.29

Price/Book(x)

2.06

3.31

1.06

1.19

1.34

Yield(%)

0.10

0.09

0.22

0.00

EV/Net Sales(x)

2.36

3.05

1.07

0.99

EV/Core EBITDA(x)

56.08

25.07

7.30

5.86

5.95

EV/EBIT(x)

-38.24

35.01

8.94

7.20

7.24

EV/CE(x)

1.57

2.24

1.01

0.93

1.02

M Cap / Sales

2.00

2.50

0.89

0.93

0.94

Growth Ratio

Net Sales Growth(%)

30.31

19.83

2.81

3.60

-10.31

Core EBITDA Growth(%)

-54.91

-0.83

-10.65

5.67

-14.22

EBIT Growth(%)

-192.36

-13.03

-10.42

4.63

-17.14

PAT Growth(%)

-515.39

-33.09

-24.49

2.44

-15.85

EPS Growth(%)

-173.44

-12.16

-22.11

2.45

-15.55

Financial Stability Ratios

Total Debt/Equity(x)

0.55

0.80

0.27

0.11

0.09

Current Ratio(x)

1.59

1.38

1.54

3.46

3.39

Quick Ratio(x)

1.28

1.06

1.22

2.96

2.88

Interest Cover(x)

-1.62

5.66

10.07

22.35

36.44

Total Debt/Mcap(x)

0.26

0.24

0.26

0.09

0.06